Evidence map›Paper›PMID 29712918›Full record

ArticleScientific reports2018

High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages.

Manabu Inoue, Mamiko Niki, Yuriko Ozeki, Sachiyo Nagi, Evans Asena Chadeka, Takehiro Yamaguchi, Mayuko Osada-Oka, Kenji Ono, Tetsuya Oda, Faith Mwende and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Manabu InoueDepartment of Bacteriology and Virology, Osaka-City University Graduate School of Medicine, Osaka, Japan.
Mamiko NikiDepartment of Bacteriology and Virology, Osaka-City University Graduate School of Medicine, Osaka, Japan.
Yuriko OzekiDepartment of Bacteriology, Niigata University School of Medicine, Niigata, Japan. yuriozeki@med.niigata-u.ac.jp.
Sachiyo NagiDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN) and the Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan.
Evans Asena ChadekaDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN) and the Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan.
Takehiro YamaguchiDepartment of Bacteriology, Niigata University School of Medicine, Niigata, Japan.
Mayuko Osada-OkaFood Hygiene and Environmental Health, Division of Applied Life Science, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.ORCID 0000-0001-9698-6940
Kenji OnoMicrobiological Research Institute, Otsuka Pharmaceutical, Tokushima, Japan.
Tetsuya OdaMicrobiological Research Institute, Otsuka Pharmaceutical, Tokushima, Japan.
Faith MwendeEastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute, Nairobi, Kenya.
Yukihiro KanekoDepartment of Bacteriology and Virology, Osaka-City University Graduate School of Medicine, Osaka, Japan.
Makoto MatsumotoMicrobiological Research Institute, Otsuka Pharmaceutical, Tokushima, Japan.
Satoshi KanekoDepartment of Eco-Epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Yoshio IchinoseNagasaki University Institute of Tropical Medicine(NUITM)-Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Sammy M NjengaEastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute, Nairobi, Kenya.
Shinjiro HamanoDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN) and the Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan.
Sohkichi MatsumotoDepartment of Bacteriology, Niigata University School of Medicine, Niigata, Japan. sohkichi@med.niigata-u.ac.jp.
Kenya Medical Research Institute · KEOsaka City University · JPOtsuka (Japan) · JPNagasaki University · JPNiigata University · JPKyoto Prefectural University · JPUniversity of Niigata Prefecture · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune responses to parasitic pathogens are affected by the host physiological condition. High-density lipoprotein (HDL) and low-density lipoprotein (LDL) are transporters of lipids between the liver and peripheral tissues, and modulate pro-inflammatory immune responses. Pathogenic mycobacteria are parasitic intracellular bacteria that can survive within macrophages for a long period. Macrophage function is thus key for host defense against mycobacteria. These basic facts suggest possible effects of HDL and LDL on mycobacterial diseases, which have not been elucidated so far. In this study, we found that HDL and not LDL enhanced mycobacterial infections in human macrophages. Nevertheless, we observed that HDL remarkably suppressed production of tumor necrosis factor alpha (TNF-α) upon mycobacterial infections. TNF-α is a critical host-protective cytokine against mycobacterial diseases. We proved that toll-like receptor (TLR)-2 is responsible for TNF-α production by human macrophages infected with mycobacteria. Subsequent analysis showed that HDL downregulates TLR2 expression and suppresses its intracellular signaling pathways. This report demonstrates for the first time the substantial action of HDL in mycobacterial infections to human macrophages.

Indexed as

CytokinesGene Expression RegulationHumansLipoproteins, HDLLipoproteins, LDLMacrophagesMycobacterium InfectionsMycobacterium tuberculosisSignal TransductionToll-Like Receptor 2Tumor Necrosis Factor-alphaCytokinesLipoproteins, HDLLipoproteins, LDLTLR2 protein, humanToll-Like Receptor 2Tumor Necrosis Factor-alpha

Identifiers

PMID29712918
PMCPMC5928146
OpenAlexW2806448551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.